BACKGROUND: Coagulopathies are a major class among COVID-19 associated complications. Although anticoagulants such as unfractionated Heparin and Enoxaparin are both being used for therapeutic mitigation of COVID associated coagulopathy (CAC), differences in their clinical outcomes remain to be investigated. METHODS: We analyzed records of 1,113 patients in the Mayo Clinic Electronic Health Record (EHR) database who were admitted to the hospital for COVID-19 between April 4, 2020 and August 31, 2020, including 19 different Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Among this patient population, we compared cohorts of patients who received different types of anticoagulants, including 441 patients who received unfractionated Heparin and 166 patients who received Enoxaparin. Clinical outcomes at 28 days were compared, and propensity score matching was used to control for potential confounding variables including: demographics, comorbidities, ICU status, chronic kidney disease stage, and oxygenation status. Patients with a history of acute kidney injury and patients who received multiple types of anticoagulants were excluded from the study. FINDINGS: We find that COVID-19 patients administered unfractionated Heparin but not Enoxaparin have higher rates of 28-day mortality (risk ratio: 4.3; 95% Confidence Interval [C.I.].: [1.8, 10.2]; p-value: 8.5e-4, Benjamini Hochberg [BH] adjusted p-value: 2.1e-3), after controlling for potential confounding factors. INTERPRETATION: This study emphasizes the need for mechanistically investigating differential modulation of the COVID-associated coagulation cascades by Enoxaparin versus unfractionated Heparin. FUNDING: This work was supported by Nference, inc.
BACKGROUND: Coagulopathies are a major class among COVID-19 associated complications. Although anticoagulants such as unfractionated Heparin and Enoxaparin are both being used for therapeutic mitigation of COVID associated coagulopathy (CAC), differences in their clinical outcomes remain to be investigated. METHODS: We analyzed records of 1,113 patients in the Mayo Clinic Electronic Health Record (EHR) database who were admitted to the hospital for COVID-19 between April 4, 2020 and August 31, 2020, including 19 different Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Among this patient population, we compared cohorts of patients who received different types of anticoagulants, including 441 patients who received unfractionated Heparin and 166 patients who received Enoxaparin. Clinical outcomes at 28 days were compared, and propensity score matching was used to control for potential confounding variables including: demographics, comorbidities, ICU status, chronic kidney disease stage, and oxygenation status. Patients with a history of acute kidney injury and patients who received multiple types of anticoagulants were excluded from the study. FINDINGS: We find that COVID-19 patients administered unfractionated Heparin but not Enoxaparin have higher rates of 28-day mortality (risk ratio: 4.3; 95% Confidence Interval [C.I.].: [1.8, 10.2]; p-value: 8.5e-4, Benjamini Hochberg [BH] adjusted p-value: 2.1e-3), after controlling for potential confounding factors. INTERPRETATION: This study emphasizes the need for mechanistically investigating differential modulation of the COVID-associated coagulation cascades by Enoxaparin versus unfractionated Heparin. FUNDING: This work was supported by Nference, inc.
Authors: S Laporte; J Liotier; L Bertoletti; F-X Kleber; G F Pineo; C Chapelle; N Moulin; P Mismetti Journal: J Thromb Haemost Date: 2011-03 Impact factor: 5.824
Authors: Sabina A Murphy; Charles Michael Gibson; David A Morrow; Frans Van de Werf; Ian B Menown; Shaun G Goodman; Kenneth W Mahaffey; Marc Cohen; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald Journal: Eur Heart J Date: 2007-06-28 Impact factor: 29.983
Authors: Stefano Barco; Roland Bingisser; Giuseppe Colucci; André Frenk; Bernhard Gerber; Ulrike Held; Francois Mach; Lucia Mazzolai; Marc Righini; Thomas Rosemann; Tim Sebastian; Rebecca Spescha; Stefan Stortecky; Stephan Windecker; Nils Kucher Journal: Trials Date: 2020-09-09 Impact factor: 2.279
Authors: Tyler Wagner; Fnu Shweta; Karthik Murugadoss; Samir Awasthi; A J Venkatakrishnan; Sairam Bade; Arjun Puranik; Martin Kang; Brian W Pickering; John C O'Horo; Philippe R Bauer; Raymund R Razonable; Paschalis Vergidis; Zelalem Temesgen; Stacey Rizza; Maryam Mahmood; Walter R Wilson; Douglas Challener; Praveen Anand; Matt Liebers; Zainab Doctor; Eli Silvert; Hugo Solomon; Akash Anand; Rakesh Barve; Gregory Gores; Amy W Williams; William G Morice; John Halamka; Andrew Badley; Venky Soundararajan Journal: Elife Date: 2020-07-07 Impact factor: 8.140
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-10 Impact factor: 3.944
Authors: Colin Pawlowski; Tyler Wagner; Arjun Puranik; Karthik Murugadoss; Liam Loscalzo; A J Venkatakrishnan; Rajiv K Pruthi; Damon E Houghton; John C O'Horo; William G Morice; Amy W Williams; Gregory J Gores; John Halamka; Andrew D Badley; Elliot S Barnathan; Hideo Makimura; Najat Khan; Venky Soundararajan Journal: Elife Date: 2020-08-17 Impact factor: 8.140
Authors: Reid McMurry; Patrick Lenehan; Samir Awasthi; Eli Silvert; Arjun Puranik; Colin Pawlowski; A J Venkatakrishnan; Praveen Anand; Vineet Agarwal; John C O'Horo; Gregory J Gores; Amy W Williams; Andrew D Badley; John Halamka; Abinash Virk; Melanie D Swift; Katie Carlson; Deeksha Doddahonnaiah; Anna Metzger; Nikhil Kayal; Gabi Berner; Eshwan Ramudu; Corinne Carpenter; Tyler Wagner; Ajit Rajasekharan; Venky Soundararajan Journal: Med (N Y) Date: 2021-07-01
Authors: David M Maslove; Stephanie Sibley; J Gordon Boyd; Ewan C Goligher; Laveena Munshi; Isaac I Bogoch; Bram Rochwerg Journal: Chest Date: 2021-10-13 Impact factor: 10.262